Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report

por Fahrleitner-Pammer, A., Wagner, D., Krisper, P., Amrein, K., Dimai, H.
Publicado 2016

Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

por Fahrleitner-Pammer, A., Langdahl, B. L., Marin, F., Jakob, F., Karras, D., Barrett, A., Ljunggren, Ö., Walsh, J. B., Rajzbaum, G., Barker, C., Lems, W. F.
Publicado 2010

Serum sclerostin levels in renal cell carcinoma patients with bone metastases

por Wibmer, C., Amrein, K., Fahrleitner-Pammer, A., Gilg, M. M., Berghold, A., Hutterer, G. C., Maurer-Ertl, W., Gerger, A., Leithner, A., Pichler, M., Szkandera, J.
Publicado 2016

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

por Jakob, F, Oertel, H, Langdahl, B, Ljunggren, O, Barrett, A, Karras, D, Walsh, J B, Fahrleitner-Pammer, A, Rajzbaum, G, Barker, C, Lems, W F, Marin, F
Publicado 2012

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

por Jakob, F, Oertel, H, Langdahl, B, Ljunggren, O, Barrett, A, Karras, D, Walsh, J B, Fahrleitner-Pammer, A, Rajzbaum, G, Barker, C, Lems, W F, Marin, F
Publicado 2012

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 1...

por Hadji, P., Papaioannou, N., Gielen, E., Feudjo Tepie, M., Zhang, E., Frieling, I., Geusens, P., Makras, P., Resch, H., Möller, G., Kalouche-Khalil, L., Fahrleitner-Pammer, A.
Publicado 2015

Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study

por Schwetz, V., Schnedl, C., Urbanic-Purkart, T., Trummer, C., Dimai, H. P., Fahrleitner-Pammer, A., Putz-Bankuti, C., Christopher, K. B., Obermayer-Pietsch, B., Pieber, T. R., Dobnig, H., Amrein, K.
Publicado 2017

Efficacy of teriparatide compared with risedronate on FRAX(®)-defined major osteoporotic fractures: results of the VERO clinical trial

por Body, J.-J., Marin, F., Kendler, D.L., Zerbini, C.A.F., López-Romero, P., Möricke, R., Casado, E., Fahrleitner-Pammer, A., Stepan, J.J., Lespessailles, E., Minisola, S., Geusens, P.
Publicado 2020

Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, G...

por Fahrleitner-Pammer, A., Papaioannou, N., Gielen, E., Feudjo Tepie, M., Toffis, C., Frieling, I., Geusens, P., Makras, P., Boschitsch, E., Callens, J., Anastasilakis, A. D., Niedhart, C., Resch, H., Kalouche-Khalil, L., Hadji, P.
Publicado 2017

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group

por Bilezikian, J.P., Lin, C.J.F., Brown, J.P., Wang, A.T., Yin, X., Ebeling, P.R., Fahrleitner-Pammer, A., Franek, E., Gilchrist, N., Miller, P.D., Simon, J.A., Valter, I., Zerbini, C.A.F., Libanati, C., Chines, A.
Publicado 2019